Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 234.27 Delayed Data As of Dec 02 |  +14.02 / +6.37%Today’s Change | 117.58 Today|||52-Week Range 236.80 | +38.15% Year-to-Date |
Latest ALNY News | Press Releases
| Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report? Dec 01 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 220.25 |
| Today’s open | 217.52 |
| Day’s range | 217.52 - 235.41 |
| Volume | 44,875 |
| Average volume (3 months) | 1,048,947 |
| Market cap | $28.8B |
Data as of 4:00pm ET, 12/02/2022
Growth & Valuation
| Earnings growth (last year) | +3.54% |
| Earnings growth (this year) | -26.19% |
| Earnings growth (next 5 years) | +38.33% |
| Revenue growth (last year) | +71.31% |
| P/E ratio | NM |
| Price/Sales | 23.79 |
| Price/Book | 47.91 |
Competitors
Data as of 4:00pm ET, 12/02/2022
Financials
| Next reporting date | February 9, 2023 |
| EPS forecast (this quarter) | -$1.83 |
| Annual revenue (last year) | $844.3M |
| Annual profit (last year) | -$852.8M |
| Net profit margin | -101.01% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
